Drug intelligence / Profile preview

IM-23

Development stage: Phase 1
Lead developer: Immunochina Pharmaceuticals
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IM-23 is an investigational chimeric antigen receptor T cell (CAR-T) therapy targeting CD123 (interleukin-3 receptor subunit alpha), developed for the treatment of CD123-positive acute myeloid leukemia (AML). The therapy involves engineering a patient's own T cells to express a CAR that recognizes and binds to CD123 on leukemic cells, enabling targeted immune-mediated destruction of these cancerous cells. Developed by Beijing Imunopharm Technology Co., Ltd., IM-23 has reached Phase 1 clinical trials in AML patients[2][4].

Targets

IL3RA (Interleukin 3 Receptor)

Beyond the preview

Go deeper on IM-23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM-23.

Explore the full profile